clinical trial · NCT04222972
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche·phase3·terminated·n = 223
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesPralsetinibCarboplatinCisplatinPemetrexedPembrolizumabGemcitabinePaclitaxelNab-Paclitaxel
brief summary
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for participants with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease.
started
Jul 24, 2020
primary completion
Jan 27, 2025
completion
Jan 27, 2025
last updated
Mar 5, 2026
official title
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol